24-Hour Data
AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial
AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile